专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

US09249409B2 Method for detection of cancer 有权
标题翻译：癌症检测方法
公开(公告)号：US09249409B2
公开(公告)日：2016-02-02
申请号：US12739689
申请日：2008-10-23
申请人： Fumiyoshi Okano , Kana Suzuki
发明人： Fumiyoshi Okano , Kana Suzuki
IPC分类号： G01N33/53 , G01N33/574 , C12N15/10
CPC分类号： C12N15/1037 , G01N33/57484 , G01N2333/4727 , G01N2333/723
摘要： A method for detecting a cancer(s) based on an expression of prescribed polypeptides is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing in serum derived from cancer-bearing living body. Because these polypeptides react with antibodies specifically existing in serum of a cancer patient, cancers in a living body can be detected by measuring the antibody in a sample. Cancers in a living body can also be detected by measuring the antigen protein of the antibody per se or mRNA encoding it.
摘要翻译：公开了一种基于规定多肽的表达检测癌症的方法。通过使用来自犬睾丸的cDNA文库和来自携带癌症的狗的血清的SEREX方法，分离这些多肽作为与存在于含有癌的活体的血清中存在的抗体结合的多肽。因为这些多肽与癌症患者血清中特异性存在的抗体反应，所以可以通过测量样品中的抗体来检测活体中的癌症。也可以通过测量抗体本身的抗原蛋白或编码它的mRNA来检测活体中的癌症。

82. 发明申请

US20150252426A1 METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO ANDROGEN RECEPTOR THERAPY 有权
标题翻译：用于确定对雄激素受体治疗的耐药性的方法和组合物
公开(公告)号：US20150252426A1
公开(公告)日：2015-09-10
申请号：US14417515
申请日：2013-07-26
申请人： Aragon Pharmaceuticals, Inc.
发明人： James David Joseph , Jeffrey H. Hager , John Lee Sensintaffar , Nhin Lu , Jing Qian , Nicholas D. Smith
IPC分类号： C12Q1/68 , G01N33/574 , A61K45/06 , C07K16/28 , A61K31/4439 , C07K14/72
CPC分类号： A61K31/4184 , A61K31/4166 , A61K31/4439 , A61K38/09 , A61K45/06 , C07K14/721 , C07K16/2869 , C12Q1/6886 , C12Q1/6897 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/57492 , G01N2333/723 , A61K2300/00
摘要： Described herein are modified androgen receptor polypeptides that are resistant to inhibition by an androgen receptor inhibitor. Described herein are compositions, combinations, and kits containing the modified androgen receptor polypeptides and methods of using the modified androgen receptor polypeptides. Also described herein are methods of using the modified androgen receptor polypeptides as screening agents for the identification and design of third-generation androgen receptor modulators. Also described herein are third-generation androgen receptor modulators that inhibit the activity of the modified androgen receptor polypeptides. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions, including cancers, such as castration resistant prostate cancers, that are mediated or dependent upon androgen receptors.
摘要翻译：本文描述的是对雄激素受体抑制剂的抑制有抗性的修饰的雄激素受体多肽。本文描述的是含有修饰的雄激素受体多肽的组合物，组合和试剂盒，以及使用修饰的雄激素受体多肽的方法。本文还描述了使用修饰的雄激素受体多肽作为用于鉴定和设计第三代雄激素受体调节剂的筛选剂的方法。本文还描述了抑制修饰的雄激素受体多肽的活性的第三代雄激素受体调节剂。还描述了包括本文所述化合物的药物组合物和药物，以及使用这种雄激素受体调节剂单独和与其它化合物组合用于治疗疾病或病症（包括癌症如阉割抗性前列腺癌）的方法，其中是介导的或依赖于雄激素受体。

83. 发明申请

US20150212089A1 CIRCULATING TUMOR CELL DIAGNOSTICS FOR BIOMARKERS PREDICTIVE OF RESISTANCE TO ANDROGEN RECEPTOR (AR) TARGETED THERAPIES 审中-公开
标题翻译：用于生物标志物的循环肿瘤细胞诊断预测耐受受体（AR）靶向治疗
公开(公告)号：US20150212089A1
公开(公告)日：2015-07-30
申请号：US14609356
申请日：2015-01-29
申请人： EPIC SCIENCES, INC.
发明人： Ryan DITTAMORE
IPC分类号： G01N33/574 , C12Q1/68
CPC分类号： G01N33/57434 , C12Q1/6886 , C12Q2600/106 , G01N2333/4742 , G01N2333/723 , G01N2800/52
摘要： The disclosure provides a method of predicting resistance to androgen receptor (AR) targeted therapy in a prostate cancer patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to identify circulating tumor cells (CTCs), and (b) based on said direct analysis further determining the presence of a biomarker signature that is predictive of resistance to AR targeted therapy in the prostate cancer patient, wherein the biomarker signature comprises CK+, AR+, nucleoli+ CTCs in a subpopulation of said CTCs. The present disclosure also provides a method of predicting resistance to taxane-based chemotherapy in a prostate cancer patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to identify circulating tumor cells (CTCs), and (b) based on said direct analysis further determining the presence of a biomarker signature that is predictive of resistance to taxane-based chemotherapy in the prostate cancer patient, wherein the biomarker signature comprises CK+, AR−, nucleoli+, small size in a subpopulation of said CTCs.
摘要翻译：本公开提供了一种预测前列腺癌患者中对雄激素受体（AR）靶向治疗的抗性的方法，包括（a）进行包括免疫荧光染色和从患者获得的血液样品中的有核细胞的形态学表征的直接分析以鉴定循环肿瘤细胞（CTC）和（b）基于所述直接分析，进一步确定预测前列腺癌患者对AR靶向治疗的抗性的生物标志物标志的存在，其中生物标志物特征包括CK +，AR +，核仁+ CTC 所述反恐委员会的子群体。本公开还提供了一种预测前列腺癌患者中基于紫杉烷类化疗的抗性的方法，包括（a）进行包括免疫荧光染色和从患者获得的血液样品中的有核细胞的形态学表征的直接分析以鉴定循环肿瘤细胞（CTC），和（b）基于所述直接分析，进一步确定预测前列腺癌患者中基于紫杉烷类化疗的抗性的生物标志物签名的存在，其中生物标志物标志包括CK +，AR-，核仁+，小在所述CTC的亚群中的大小。

84. 发明申请

US20150160103A1 TISSUE STAINING METHOD, TISSUE EVALUATION METHOD AND BIOSUBSTANCE DETECTION METHOD 审中-公开
标题翻译：组织染色方法，组织评价方法和生物传感器检测方法
公开(公告)号：US20150160103A1
公开(公告)日：2015-06-11
申请号：US14626329
申请日：2015-02-19
申请人： Konica Minolta, Inc.
发明人： Takuji AIMIYA , Hideki Gouda , Hisatake Okada , Yasushi Nakano
IPC分类号： G01N1/30 , G01N33/74 , G01N33/58
CPC分类号： G01N1/30 , B82Y15/00 , B82Y30/00 , G01N21/6428 , G01N33/582 , G01N33/588 , G01N33/74 , G01N33/743 , G01N2001/302 , G01N2021/6441 , G01N2333/71 , G01N2333/723 , G01N2333/91205
摘要： A tissue staining method which comprises: staining a tissue with a staining reagent wherein a biosubstance recognition site is bonded to particles carrying multiple fluorescent substances accumulated therein; in the stained tissue, counting fluorescent points or measuring fluorescent brightness; and evaluating the expression level of a biosubstance, which matches the biosubstance recognition site, in the aforesaid tissue on the basis of the number of the fluorescent points or fluorescent brightness that was measured.
摘要翻译：一种组织染色方法，包括：用染色试剂染色组织，其中生物素识别位点与携带其中积聚的多种荧光物质的颗粒结合; 在染色的组织中，计数荧光点或测量荧光亮度; 并根据测定的荧光点数或荧光亮度，评价与上述组织中生物素识别位点相符合的生物体的表达水平。

85. 发明申请

US20150141391A1 SYSTEMS AND METHODS FOR DETERMINING A TREATMENT COURSE OF ACTION 审中-公开
标题翻译：用于确定治疗疗程的系统和方法
公开(公告)号：US20150141391A1
公开(公告)日：2015-05-21
申请号：US14513501
申请日：2014-10-14
申请人： The Regents of the University of Michigan
发明人： Arul M. Chinnaiyan , Dan Robinson , Yi-Mi Wu
IPC分类号： C12Q1/68 , C07K14/72
CPC分类号： C12Q1/6886 , C07K14/70567 , C07K14/721 , C12Q2600/106 , C12Q2600/156 , G01N33/57415 , G01N33/57442 , G01N2333/723
摘要： The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer.
摘要翻译：本公开涉及确定治疗疗程的方法。特别地，本公开涉及编码雌激素受体的基因中的突变及其与对癌症的雌激素疗法的反应性的关联。

86. 发明授权

US08987319B2 Selective androgen receptor modulators 有权
标题翻译：选择性雄激素受体调节剂
公开(公告)号：US08987319B2
公开(公告)日：2015-03-24
申请号：US13576754
申请日：2011-02-04
申请人： Chris P. Miller
发明人： Chris P. Miller
IPC分类号： A61K31/40 , C07D209/88
CPC分类号： C07D209/88 , C07D209/94 , G01N33/743 , G01N2333/723 , G01N2500/04 , G01N2500/10
摘要： This invention provides compounds of Formula (I), (Ia), (Ib), (Ic), (II), (IIa) or (III) and or salts thereof, pharmaceutical compositions comprising a compound of Formula (I), (Ia), (Ib), (Ic), (II), (IIa) or (III) and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type II diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of Formula (I), (Ia), (Ib), (Ic), (II), (IIa) or (III) and intermediates useful in the preparation of same.
摘要翻译：本发明提供式（I），（Ia），（Ib），（Ic），（II），（IIa）或（III）及其盐的化合物，其包含式（I） Ia），（Ib），（Ic），（II），（IIa）或（III）和药学上可接受的赋形剂，调节雄激素受体的方法，治疗由雄激素受体调节剂有益治疗的疾病的方法（例如，肌肉减少症，前列腺癌，避孕，II型糖尿病相关疾病或疾病，贫血，抑郁症和肾脏疾病）和制备式（I），（Ia），（Ib），（Ic），（II） IIa）或（III）和可用于制备其的中间体。

87. 发明授权

US08927297B2 Methods to measure dissociation rates for ligands that form reversible covalent bonds 有权
标题翻译：测量形成可逆共价键的配体的解离速率的方法
公开(公告)号：US08927297B2
公开(公告)日：2015-01-06
申请号：US12850117
申请日：2010-08-04
申请人： Dionisios Rentzeperis , Marta Cristina Abad , Ludmila A. Barnakova , Frank A. Lewandowski , Cynthia M. Milligan
发明人： Dionisios Rentzeperis , Marta Cristina Abad , Ludmila A. Barnakova , Frank A. Lewandowski , Cynthia M. Milligan
IPC分类号： G01N33/53 , G01N33/68
CPC分类号： G01N33/6848 , G01N2333/723
摘要： The crystal structure of the ligand binding domain of ERR-α in complex with a ligand that forms a reversible thioether bond to Cys325 of ERR-α, methods to measure dissociation rates for ligands that form reversible covalent bonds, and methods to design ligands that form reversible covalent bonds for use as modulators of ERR-α activity are disclosed. The crystal structure and methods provide a novel molecular mechanism for modulation of the activity of ERR-α and provide the basis for rational drug design to obtain potent specific ligands for use as modulators of the activity of this new drug target.
摘要翻译：与ERR-α的Cys325形成可逆硫醚键的配体复合物中ERR-α的配体结合结构域的晶体结构，测量形成可逆共价键的配体的解离速率的方法，以及设计形成可逆共价键的配体的方法公开了用作ERR-α活性调节剂的可逆共价键。晶体结构和方法为调节ERR-α的活性提供了新的分子机制，为合理的药物设计提供依据，以获得有效的特异性配体，用作这种新药物靶标活性的调节剂。

88. 发明授权

US08841269B2 Polynucleotides for use in treating and diagnosing cancers 有权
标题翻译：用于治疗和诊断癌症的多核苷酸
公开(公告)号：US08841269B2
公开(公告)日：2014-09-23
申请号：US13033056
申请日：2011-02-23
申请人： Gary Guishan Xiao
发明人： Gary Guishan Xiao
IPC分类号： C12N15/11
CPC分类号： G01N33/574 , C12N15/111 , C12N15/113 , C12N15/1138 , C12N2310/14 , C12N2310/141 , C12N2320/10 , C12N2320/30 , C12Q1/6886 , C12Q2600/112 , C12Q2600/156 , C12Q2600/178 , G01N2333/723 , G01N2800/52
摘要： The present invention provides methods for increasing sensitivity of cancer cells to an antiestrogen agent, such as a selective estrogen receptor modulator (SERM). The methods include administering to the subject a polynucleotide in an amount effective to increase the antiestrogen agent sensitivity of the cancer cells. The cancer cells may be estrogen receptor positive, such as ER-α66 positive or ER-α36 positive, prior to the administering. Also provided are methods for decreasing the amount of estrogen receptor present in a cancer cell, methods for determining whether antiestrogen agent sensitivity of cancer cells in a subject can be increased, methods for diagnosing whether a subject has, or is at risk for developing, cancer, and methods for identifying an agent that increases the amount of let-7 miRNA in a cell.
摘要翻译：本发明提供了增加癌细胞对抗雌激素剂如选择性雌激素受体调节剂（SERM）的敏感性的方法。所述方法包括向受试者施用有效增加癌细胞抗雌激素剂敏感性的量的多核苷酸。在给药前，癌细胞可能是雌激素受体阳性，如ER-α66阳性或ER-α36阳性。还提供了减少癌细胞中存在的雌激素受体量的方法，用于确定是否可以增加受试者中癌细胞的抗雌激素剂敏感性的方法，诊断受试者是否具有发展癌症风险的方法以及用于鉴定增加细胞中let-7 miRNA的量的试剂的方法。

89. 发明申请

US20130344510A1 IDENTIFICATION OF CANCER PATIENTS LIKELY TO BENEFIT FROM RADIATION THERAPY 审中-公开
标题翻译：癌症患者的鉴定有利于从辐射治疗中获益
公开(公告)号：US20130344510A1
公开(公告)日：2013-12-26
申请号：US13990727
申请日：2011-12-02
申请人： Mark Gustavson , Jason Christiansen , Anthony Martin Magliocco
发明人： Mark Gustavson , Jason Christiansen , Anthony Martin Magliocco
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/57415 , G01N2333/723 , G01N2800/52
摘要： Disclosed herein are methods of identifying suitable patients for postoperative radiotherapy based on the discovery that the quantification of ER, beyond simple positive/negative characterization, can provide valuable predictive information for the treatment of cancer, specifically breast cancer, and more particularly may predict a group more likely to respond to RT and spare patients from a potentially harmful treatment. Furthermore, the true quantification of ER expression provides a continuous recurrence risk assessment for patients being treated with tamoxifen, and therefore the standardization of the data across sites and imaging platforms significantly reduces the misclassification of patients when compared to the current standard by which ER expression is determined.
摘要翻译：本文公开了基于以下发现来鉴定合适的患者的方法：基于以下发现：除了简单的阳性/阴性表征之外，ER的定量可以提供用于治疗癌症，特别是乳腺癌的有价值的预测信息，更具体地，可以预测组更有可能对RT和备用患者进行有潜在的有害治疗。此外，ER表达的真实定量为接受他莫昔芬治疗的患者提供了连续的复发风险评估，因此与现有标准相比，跨站点和成像平台的数据标准化显着降低了患者的错误分类，决心。

90. 发明申请

US20130095170A1 METHODS AND SYSTEMS FOR IDENTIFYING AND TREATING ANTI-PROGESTIN SENSITIVE TUMORS 有权
公开(公告)号：US20130095170A1
公开(公告)日：2013-04-18
申请号：US13644872
申请日：2012-10-04
申请人： Erard Gilles
发明人： Erard Gilles
IPC分类号： G01N33/74 , C12Q1/02
CPC分类号： G01N33/57492 , A61K31/4152 , A61K31/557 , A61K31/567 , A61K31/57 , A61K31/575 , A61K45/06 , C12Q1/025 , G01N33/5011 , G01N33/574 , G01N33/743 , G01N2333/723
摘要： Methods and systems for identifying and treating a patient suspected of having a tumor susceptible to growth inhibition by anti-progestins are provided. The degree of focal distribution of the progesterone receptor can be used to identify tumors susceptible to treatment with anti-progestin therapy.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式